The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis
© Niese et al. 2010
Received: 25 February 2010
Accepted: 24 June 2010
Published: 24 June 2010
Skip to main content
© Niese et al. 2010
Received: 25 February 2010
Accepted: 24 June 2010
Published: 24 June 2010
Arginine is an amino acid that serves as a substrate for the enzymes nitric oxide synthase (NOS) and arginase, leading to synthesis of NO and ornithine, respectively. As such, arginine has the potential to influence diverse fundamental processes in the lung.
We used mice deficient in cationic amino acid transporter (CAT) 2 in models of allergic airway inflammation and pulmonary fibrosis.
We report that the arginine transport protein CAT2 was over-expressed in the lung during the induction of allergic airway inflammation. Furthermore, CAT2 mRNA was strongly induced by transgenically over-expressed IL-4, and allergen-induced expression was dependent upon signal-transducer-and-activator-of-transcription (STAT) 6. In situ mRNA hybridization demonstrated marked staining of CAT2, predominantly in scattered mononuclear cells. Analysis of allergic airway inflammation and bleomycin-induced inflammation in CAT2-deficient mice revealed that while inflammation was independent of CAT2 expression, bleomycin-induced fibrosis was dependent upon CAT2. Mechanistic analysis revealed that arginase activity in macrophages was partly dependent on CAT2.
Taken together, these results identify CAT2 as a regulator of fibrotic responses in the lung.
Recent studies have implicated amino acids, specifically tryptophan and arginine, in the regulation of immunity and tolerance. Elegant studies demonstrated an important role for tryptophan metabolism through indoleamine 2,3-dioxygenase (IDO) in inhibition of experimental asthma . However, the role of arginine transport and metabolism remains unclear. Intracellular arginine is metabolized by both the nitric oxide synthase (NOS) and arginase pathways. The product of the former, NO, has been implicated in the regulation of both inflammation and airway tone. Similarly, products of the arginase pathway, such as ornithine, are regulators of key processes involved in lung inflammation, including cell hyperplasia and collagen deposition [2, 3]. Among the transport systems that mediate L-arginine uptake, cationic amino acid transporters (CAT1, -2 or -3) are considered to be the major arginine transporters in most cells and tissues . We chose to focus on CAT2 because of its essential role in arginine transport in immune cells, including macrophages . Defining the role of arginine and its transport protein CAT2 has been aided by the generation of CAT2-deficient mice . While these mice are grossly normal, their peritoneal macrophages have a 95% decrease in L-arginine uptake and a marked impairment in NO production [5, 6]. In contrast, CAT2-deficient fibroblasts have largely intact NO production . Our studies demonstrated that CAT2 is an essential part of the host protective immune apparatus in the lung in that CAT2-deficient mice displayed baseline inflammation , identifying CAT2 as responsible for maintenance of inflammatory homeostasis. A recent publication demonstrated that CAT2-deficient mice are significantly more susceptible to the parasite T gondii and develop enhanced fibrosis and granuloma formation in response to S mansoni . Since arginine entry into the NOS and arginase pathways could have multiple effects, both positive and negative, on lung processes during pathological conditions (e.g. inflammation and fibrosis), we used CAT2-deficient mice to test the net effect of reducing transport of arginine in experimental asthma and experimental lung fibrosis.
All animal studies were approved by the Cincinnati Children's Hospital IACUC committee. Mice were bred "in house" in specific pathogen-free conditions. CAT2-deficient , STAT6-deficient  and IL-4 transgenic  mice were described previously. CAT2-deficient mice were either on the FVB/N or C57Bl/6 background. Both strains have been backcrossed for more than 10 generations.
Mice were allergen challenged as described previously [12–14]. Briefly, mice were sensitized intraperitoneally (i.p.) with ovalbumin (OVA, 100 μg) in alum (1 mg) and challenged intranasally (i.n.) with 50 μg OVA or saline. After instillation, mice were held upright until alert. Mice were sacrificed 18-24 hours following the last challenge. For the bleomycin model, mice were treated with a single dose (0.03 U/mouse) of Bleomycin intratracheally (i.t.) and sacrificed 14 days later. Bronchoalveolar lavage was performed, and cells were counted by hemocytometer and differentiated based on morphology following Diff-Quick staining of cytospin preparations.
In situ hybridization was performed as described . In brief, murine CAT2 cDNA was subcloned from Image Consortium clone 5344352 into pBluescript, linearized by Hind III and Not I digestion, and anti-sense and sense RNA probes, respectively, were generated by T3 and T7 RNA polymerase (Riboprobe Gemini Core System II transcription kit; Promega, Madison, WI). The radiolabeled [αS35-UTP] probes were hybridized and washed under high-stringency conditions.
RNA was extracted using the Trizol reagent as per the manufacturer's instructions. The cDNA probe, generated from commercially available vectors [Image Consortium clone 5344352 in pCMV-SPORT6 obtained from American Tissue Culture Collection, Rockville, MD], was liberated with NdeI and MluI, confirmed by sequencing, radiolabelled with 32P, and hybridized using standard conditions, as described previously .
Collagen accumulation was determined by measuring the content of hydroxyproline as previously described . Additionally, fibrosis was evaluated histologically. Tissues were fixed in 10% neutral buffered formalin and paraffin embedded. Sections were stained with Masson's trichrome to evaluate fibrosis. Scoring (0-3) represents evaluation of intensity and extent of fibrosis determined by an observer blinded to treatment and genotype.
Arginase activity in intact cells (peritoneal macrophages from naïve mice) was measured using incorporation of radioactive arginine as previously described . Cells (2 × 105 cells/100 μl PBS and 22 mM glucose/well of 96-well-plate) were incubated with 14C-arginine (L-[guanido-14C], NEN) for 18 hours, and 14C-urea present in the cell supernatant was metabolized with urease. Released 14CO2 was collected and measured by scintillation counting. Arginase activity in lysed macrophages was measured using the blood urea nitrogen reagent (Sigma Chemical Company, St. Louis, MO) according to established techniques [16–18].
Cytokine levels were determined by Multiplex analysis on BALF supernatant samples. Analysis was performed by Millipore using the mouse 32 cytokine/chemokine panel.
Values are reported as the mean ± standard deviation. The significance of differences between groups were analyzed by ANOVA using Prism software. Pairwise comparisons were performed by Student's t-test. Differences are considered significant if P < 0.05. Trichrome staining quantification scoring was tested by Mann-Whitney U test.
In order to address the role of CAT2 in collagen deposition, we measured hydroxyproline levels in the lungs of bleomycin-treated mice. As seen in Figure 4B, CAT2-deficient mice had increased baseline levels of hydroxyproline (P = 0.02) as we have previously reported . However, while wild type mice responded to bleomycin with increased levels of hydroxyproline, CAT2-deficient mice were unable to further increase lung fibrosis. In order to assess the fibrosis by an independent method, we stained lung tissue sections by trichrome staining. As seen in Figure 4C, both wild type and CAT2-deficient mice had areas of fibrosis and tissue consolidation accompanied by inflammation, which is typical of day 14 lung sections in bleomycin-induced fibrosis. When sections were scored for intensity and extent of involvement by an observer blinded to treatment, the level of lung tissue fibrosis/consolidation was significantly decreased in CAT2-deficient mice compared with wild type mice (Figure 4D and 4E). Control mice of either genotype did not show histological evidence of fibrosis/consolidation or inflammation (Figure 4C, D and data not shown).
Recent studies have suggested a role for arginine transport and metabolism in a variety of inflammatory disorders. In this report, we used CAT2-deficient mice to test the role of arginine transport in lung inflammatory conditions, including experimental asthma and bleomycin-induced lung fibrosis. Our studies revealed several novel findings. First, we demonstrate that CAT2 mRNA expression is induced in experimental asthma and that the main cell type expressing it is a mononuclear cell most consistent with alveolar macrophages. Second, we demonstrate that CAT2 is required for bleomycin-induced pulmonary fibrosis. Third, in contrast to the fibrosis data, we show that CAT2 expression is not required for lung inflammation in either allergen-induced or bleomycin-induced models. Finally, we show that CAT2 is partially required for arginase activity in macrophages, which may contribute to the development of fibrosis.
Even though CAT2 is induced highly in asthma, it is not required for experimental asthma-induced inflammation. This observation is consistent with our recent finding that arginase is not required for allergic airway inflammation, despite high level of induction . In contrast, CAT2 was recently shown to have an important, host-protective role in parasitic infestation models , similar to studies which demonstrated a role for arginase expression in host defense in models of parasite infestation (including Schistosome mansoni, Heligmosomoides polygyrus, Leishmania sp, Toxoplasma gondii and Nipostrongylus brasiliensis) [21–26]. In summary, our data suggest a divergent role for arginase I and CAT2 in allergic inflammation compared to parasitic responses. Since arginase and CAT2 are prominent products of alternatively activated macrophages, which are induced by IL-4 in both allergic and parasitic responses, our data suggest that alternatively activated macrophages evolved to combat parasitic infections and are either bystanders in allergic inflammation or have developed other effector molecules for allergic Th2-associated responses. In contrast, we have previously demonstrated that CAT2 has a suppressive role in baseline inflammation . We speculate that resident immunosuppressive macrophages require CAT2 for the maintenance of inflammatory homeostasis in the lung, whereas highly activated M2 macrophages express CAT2 but do not require it for the inflammatory process.
Similarly, the role of CAT2 in fibrosis is context-dependent. Baseline fibrosis is increased in CAT2-deficient mice as measured by the whole lung hydroxyproline assay . Interestingly, this baseline fibrosis is not evident histologically by trichrome staining, especially when slides are scored by an observer blinded to genotype and treatment. We did not assess allergen-induced fibrosis because fibrosis does not develop in the acute OVA-induced model. However, we used a well-characterized model of bleomycin-induced fibrosis, which has previously been shown to exhibit induced transcription of CAT2 . Interestingly, in this model fibrosis is dependent on CAT2 as measured by either whole lung hydroxyproline measurement or blinded quantification of trichrome staining. Since previous studies have shown that proline synthesis (often a rate-limiting step in collagen synthesis) is downstream of CAT2 and arginase, we tested the hypothesis that CAT2 is required for arginase activity in macrophages. We found a notable requirement, suggesting a possible role for arginase in the CAT2-mediated fibrosis.
The requirement for CAT2 for arginase activity in macrophages is controversial. Thompson et al.  demonstrated that CAT2-deficient macrophages and fibroblasts have increased arginase activity. However, their assay was performed with ruptured cells and exogenously added arginine (250 mM; Km for arginase is ~5 mM) thus circumventing the function of arginine transport into the cell. Yeramian et al.  demonstrated decreased arginine catabolism into ornithine and polyamines in CAT2-deficient alternatively activated macrophages, suggesting the requirement for CAT2 for arginase activity in intact cells. In order to directly test the role of CAT2 in arginase activity, we used the whole cell arginase activity assay . Importantly, as opposed to the assay used by Thompson et al.  and by us in lysed macrophages (Figure 5B) that assesses the arginase activity in ruptured cells or tissues and is thus primarily a reflection of the amount of arginase expression, the whole cell assay accounts for the role of trans-membrane transport for arginase function. We used peritoneal macrophages since we were unable to collect sufficient numbers of lung macrophages for this assay. Our data demonstrate a partial requirement for CAT2 for arginase activity in intact macrophages, suggesting either an alternative transporter or intracellular pool of arginine can contribute to arginase activity. This is in contrast to NOS activity, which depends on arginine transport from the extracellular space [15, 28, 29].
In summary, we have described a pathway (involving CAT2 and arginine homeostasis) not previously examined in the context of lung inflammation and fibrosis. We find that while CAT2 is highly upregulated in experimental asthma, it does not have a role in allergic airway inflammation. Rather, CAT2 is critically important for interstitial lung fibrosis.
bronchoalveolar lavage fluid
cationic amino acid transporter
nitric oxide synthase
The authors wish to thank Laura Koch, Amy Hajek and Erin Zoller for technical assistance; Dr Keith Stringer for assistance with in situ hybridization; Drs. Carol MacLeod, Sidney Morris and Ariel Munitz for critical discussions, reagents and technical advice; and Shawna Hottinger for final edits to the manuscript. This study was funded in part by the March of Dimes grant FY06-345 (to NZ) and by NIH R01 AI53479-01 (to MER and NZ). Neither the March of Dimes nor the NIH participated in study design, collection, analysis or interpretation of data, writing of the manuscript or the decision to submit the manuscript. MGC is currently at Technical Resources International, Inc. in Bethesda, Maryland.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.